0001578563-21-000036.txt : 20211007
0001578563-21-000036.hdr.sgml : 20211007
20211007211800
ACCESSION NUMBER: 0001578563-21-000036
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211007
FILED AS OF DATE: 20211007
DATE AS OF CHANGE: 20211007
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BAYER AKTIENGESELLSCHAFT
CENTRAL INDEX KEY: 0001144145
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40881
FILM NUMBER: 211313685
BUSINESS ADDRESS:
STREET 1: BAYERWERK, GEBAEUDE W11
STREET 2: KAISER-WILHELM-ALLEE
CITY: LEVERKUSEN
STATE: 2M
ZIP: D-51368
BUSINESS PHONE: 492143081933
MAIL ADDRESS:
STREET 1: BAYERWERK, GEBAEUDE W11
STREET 2: KAISER-WILHELM-ALLEE
CITY: LEVERKUSEN
STATE: 2M
ZIP: D-51368
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bayer World Investments B.V.
CENTRAL INDEX KEY: 0001820027
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40881
FILM NUMBER: 211313686
BUSINESS ADDRESS:
STREET 1: ENERGIEWEG 1
CITY: MIJDRECHT
STATE: P7
ZIP: 3641
BUSINESS PHONE: 00 31 297 280 666
MAIL ADDRESS:
STREET 1: ENERGIEWEG 1
CITY: MIJDRECHT
STATE: P7
ZIP: 3641
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pyxis Oncology, Inc.
CENTRAL INDEX KEY: 0001782223
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831160910
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 BOYLSTON STREET
STREET 2: SUITE 1555
CITY: BOSTON
STATE: MA
ZIP: 02199
BUSINESS PHONE: (617) 351-2575
MAIL ADDRESS:
STREET 1: 800 BOYLSTON STREET
STREET 2: SUITE 1555
CITY: BOSTON
STATE: MA
ZIP: 02199
3
1
primary_doc.xml
PRIMARY DOCUMENT
X0206
3
2021-10-07
0
0001782223
Pyxis Oncology, Inc.
PYXO
0001820027
Bayer World Investments B.V.
ENERGIEWEG 1
MIJDRECHT
P7
3641RT
NETHERLANDS
0
0
1
0
0001144145
BAYER AKTIENGESELLSCHAFT
BAYERWERK, GEBAEUDE W11
KAISER-WILHELM-ALLEE 1
LEVERKUSEN
2M
51373
GERMANY
0
0
1
0
Series A Convertible Preferred Stock
Common Stock
1786831
D
Series B Convertible Preferred Stock
Common Stock
955507
D
Shares of Series A and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") have no expiration date and, as of the date of this filing, are convertible, at the option of the Reporting Persons, into shares of the Issuer's common stock at a 6.359-for-1 conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares).
Reflects that each 6.359 shares of Preferred Stock will convert automatically into one share of the Issuer's common stock at the closing of the Issuer's initial public offering, for no additional consideration (subject to the payment of cash in lieu of any fractional shares).
The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Bayer World Investments B.V., By: /s/ Patrick Lennaerts, Name: Patrick Lennaerts, Title: Managing Director
2021-10-07
Bayer Aktiengesellschaft, By: /s/ Christian Bank, Name: Christian Bank, Title: Head of Legal Mergers & Acquisitions
2021-10-07